[Therapeutic indications targeting etiology. (With the exception of primary progressive forms)]

D Brassat

[Therapeutic indications targeting etiology. (With the exception of primary progressive forms)]

Rev Neurol (Paris). 2001 Sep;157(8-9 Pt 2):1014-28.

[Article in French]

Author

D Brassat¹

Affiliation

¹ Fédération de Neurologie, Hopital Purpan, place du Dr Baylac, 31059 Toulouse.

PMID: 11787332

Abstract

On the subject of the treatment of Multiple Sclerosis, JM Charcot stated in 1877 that "the time has not yet come when such a subject can be seriously considered". Fortunately such point of view is no more up to date. This chapter will review the available treatment for relapsing-remitting and secondary progressive Multiple Sclerosis. The immunosuppressive drugs and steroids have been used for many years. Immunomodulation appeared more recently. A review of the evidence on the use of those drugs will be performed.

Publication types

English Abstract
Review

MeSH terms

Adrenal Cortex Hormones / administration & dosage*
Adrenal Cortex Hormones / adverse effects
Clinical Trials as Topic
Dose-Response Relationship, Drug
Drug Administration Schedule
Humans
Immunosuppressive Agents / administration & dosage*
Immunosuppressive Agents / adverse effects
Multiple Sclerosis, Chronic Progressive / drug therapy*
Multiple Sclerosis, Chronic Progressive / etiology
Multiple Sclerosis, Chronic Progressive / immunology
Multiple Sclerosis, Relapsing-Remitting / drug therapy*
Multiple Sclerosis, Relapsing-Remitting / etiology
Multiple Sclerosis, Relapsing-Remitting / immunology
Treatment Outcome

Substances

Adrenal Cortex Hormones
Immunosuppressive Agents